These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1453203)

  • 1. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
    Wasserman R; Galili N; Ito Y; Silber JH; Reichard BA; Shane S; Womer RB; Lange B; Rovera G
    J Clin Oncol; 1992 Dec; 10(12):1879-88. PubMed ID: 1453203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
    Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
    J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
    Potter MN; Steward CG; Oakhill A
    Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
    Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
    Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
    N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
    Yamada M; Wasserman R; Lange B; Reichard BA; Womer RB; Rovera G
    N Engl J Med; 1990 Aug; 323(7):448-55. PubMed ID: 2095753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
    Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
    J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
    Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
    Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
    Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
    J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.
    Roberts WM; Estrov Z; Ouspenskaia MV; Johnston DA; McClain KL; Zipf TF
    N Engl J Med; 1997 Jan; 336(5):317-23. PubMed ID: 9011783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association.
    Uderzo C; Valsecchi MG; Bacigalupo A; Meloni G; Messina C; Polchi P; Di Girolamo G; Dini G; Miniero R; Locatelli F
    J Clin Oncol; 1995 Feb; 13(2):352-8. PubMed ID: 7844596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.